相关实验视频
Updated: Sep 19, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.8K
新型基于牛津醇的牛津醇合物:合成,DFT研究和内确认作为强大的抗糖尿病药物
Shoaib Khan1, Tayyiaba Iqbal1, Muhammad Bilal Khan1
1Department of Chemistry, Abbottabad University of Science and Technology, Abbottabad 22500, Pakistan.
Computational biology and chemistry
|June 18, 2025
概括
新型氧沙衍生氧沙衍生物通过抑制α-氨酶和α-葡萄糖酶,表现出强烈的抗糖尿病活性. 同类物8被认为是开发新型糖尿病治疗的有希望的化合物.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 计算化学的计算化学
背景情况:
- 糖尿病是一种严重的代谢障碍,需要有效的治疗干预措施.
- 现有的治疗方法可能有局限性,需要开发新的抗糖尿病药物.
- 氧沙和氧沙的支架因其多样化的生物活动而闻名.
研究的目的:
- 为了合成和评估新型的抗糖尿病潜力的氧沙衍生氧沙衍生品.
- 与acarbose相比,以提高效率和减少副作用的化合物进行识别.
- 为了将体内生物活动与内计算研究相关联.
主要方法:
- 合成十六种新型的氧化衍生氧化衍生品.
- 对化合物的体外查针对α-氨酶和α-葡萄糖酶酶.
- 在分析包括分子对接,DFT计算和ADMET分析.
主要成果:
- 所有合成的衍生品都显示出中度至优异的抗糖尿病活性.
- 抑制度范围为15.20 ± 0.20 2.10 ± 0.10 微米的α-氨基酶和15.70 ± 0.50 2.40 ± 0.20 微米的α-葡萄糖酶.
- 与阿卡尔和其他类似物相比,类似物8成为具有优越抗糖尿病特征的化合物.
- 计算研究支持了化合物的治疗潜力和类似药物的特性.
结论:
- 新型氧沙衍生氧沙衍生物显示出作为抗糖尿病药物的显著潜力.
- 模拟器8显示有希望的疗效和安全性,需要进一步调查.
- 结合体外和内方法的结合为开发糖尿病新疗法提供了坚实的基础.
相关概念视频
Insulin: Biosynthesis, Chemistry, and Preparation
569
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
569
Drug Discovery: Overview
8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
3.1K
The reaction of weakly electrophilic aryldiazonium (also called arenediazonium) salts with highly activated aromatic compounds leads to the formation of products with an —N=N— link, called an azo linkage. This reaction, presented in Figure 1, is known as diazo coupling and occurs without the loss of the nitrogen atoms of the aryldiazonium salt. Highly activated aromatic compounds such as phenols or arylamines favor the diazo coupling reaction. The coupling generally occurs at the...
3.1K
Oxidation of Alkenes: Syn Dihydroxylation with Osmium Tetraoxide
10.9K
Alkenes are converted to 1,2-diols or glycols through a process called dihydroxylation. It involves the addition of two hydroxyl groups across the double bond with two different stereochemical approaches, namely anti and syn. Dihydroxylation using osmium tetroxide progresses with syn stereochemistry.
10.9K
Oral Hypoglycemic Agents: Sulfonylureas
353
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
353
Oral Hypoglycemic Agents: Biguanides and Glitazones
310
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310

